FBRX
Forte Biosciences, Inc.Company Information
- Company Name
- Forte Biosciences, Inc.
- CIK
- CIK0001419041
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- FBRX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- FBRX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-30
- Last sale
- —
- Shares purchased (TTM)
- 9,680
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 20,183,346
- Shares outstanding
- 20,482,400
- Ownership
- 98.54%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 50 | 58 | 77 | 93 | 106 | 46 | 22 | 16 | 24 | 30 | 37 | 46 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 203 | 65 | 81 | 95 | 108 | 47 | 61 | 18 | 26 | 32 | 38 | 47 | ||||||
| Short Term Investments | 149 | - | - | - | - | - | 36 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 5 | 7 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 3 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Assets | 206 | 67 | 83 | 97 | 108 | 47 | 62 | 18 | 26 | 32 | 39 | 48 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 14 | 13 | 10 | 5 | 5 | 5 | 5 | 5 | 5 | 2 | 1 | 5 | ||||||
| Accrued Liabilities Current | 6 | 11 | 11 | 8 | 4 | 4 | 4 | 3 | 4 | 2 | 2 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 20 | 24 | 21 | 13 | 9 | 9 | 9 | 9 | 9 | 3 | 4 | 7 | ||||||
| Accrued Income Taxes Noncurrent | - | - | 1 | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 2 | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 22 | 25 | 22 | - | - | - | 9 | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 184 | 42 | 61 | 84 | 99 | 38 | 52 | 9 | 17 | 29 | 35 | 40 | ||||||
| Additional Paid In Capital Common Stock | 453 | 288 | 284 | 283 | 280 | 208 | 206 | 156 | 155 | 155 | 154 | 153 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | -0 | - | - | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -269 | -246 | -223 | -199 | -181 | -170 | -154 | -147 | -138 | -126 | -119 | -113 | ||||||
| Liabilities And Stockholders Equity | 206 | 67 | 83 | 97 | 108 | 47 | 62 | 18 | 26 | 32 | 39 | 48 | ||||||
| Related Party | - | - | - | - | - | 0 | - | - | 0 | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 20 | 14 | 13 | 13 | 12 | 7 | 6 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 20 | 14 | 13 | 13 | 12 | 7 | 6 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialForte Biosciences, Inc. (FBRX) — SEC Financial Statements & Analysis
Forte Biosciences, Inc. (FBRX) is a pharmaceutical preparations company, incorporated in DE. Forte Biosciences, Inc. trades on Nasdaq as: FBRX. Forte Biosciences, Inc. (FBRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Forte Biosciences, Inc. carries a market cap of $435.25M, a P/E ratio of -4.95x, a P/B ratio of 2.37x, an enterprise value of $385.62M, and an EV/EBITDA multiple of -4.29x. On profitability, it posts a Return on Equity (ROE) of -62.28%, a Return on Assets (ROA) of -56.10%, and a Return on Invested Capital (ROIC) of -141.21%. Per share, it reports EPS of $-4.29, free cash flow per share of $-3.52, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 107.14% year-over-year and EPS growth of 24.21% year-over-year. On the balance sheet, it maintains a current ratio of 10.01x, a quick ratio of 9.78x, working capital of $182.81M, a debt-to-equity ratio of 0.12x, a debt ratio of 0.11, free cash flow of $-72.03M (TTM), and net debt of $-49.63M. Figures sourced from SEC EDGAR.
- Market Cap
- $435.25M
- P/E TTM
- -4.95x
- EPS TTM
- $-4.29
- P/B TTM
- 2.37x
- ROE TTM
- -62.28%
- ROA TTM
- -56.10%
- Debt To Equity
- 0.12x
- Free Cash Flow TTM
- $-72.03M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Forte Biosciences, Inc. in?
Forte Biosciences, Inc. (FBRX) operates in the Pharmaceutical Preparations industry.
What exchange does FBRX trade on?
Forte Biosciences, Inc. (FBRX) trades on the Nasdaq.
Where is Forte Biosciences, Inc. incorporated?
Forte Biosciences, Inc. is incorporated in DE.
When was Forte Biosciences, Inc. (FBRX)'s most recent SEC filing?
Forte Biosciences, Inc. (FBRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is FBRX's market cap?
Forte Biosciences, Inc. (FBRX) has a market capitalization of $435.25M as of 2026-06-30.
What is FBRX's EPS (earnings per share)?
Forte Biosciences, Inc. (FBRX)'s trailing twelve month EPS is $-4.29 as of 2026-06-30.
What is FBRX's ROE (return on equity)?
Forte Biosciences, Inc. (FBRX)'s trailing twelve month Return on Equity (ROE) is -62.28% as of 2026-06-30.
What is FBRX's ROA (return on assets)?
Forte Biosciences, Inc. (FBRX)'s trailing twelve month Return on Assets (ROA) is -56.10% as of 2026-06-30.
What is FBRX's ROIC (return on invested capital)?
Forte Biosciences, Inc. (FBRX)'s trailing twelve month Return on Invested Capital (ROIC) is -141.21% as of 2026-06-30.
What is FBRX's EV/EBITDA?
Forte Biosciences, Inc. (FBRX)'s trailing twelve month EV/EBITDA is -4.29x as of 2026-06-30.